BIOHEBE

Biohebe provides preclinic business development and company formation for therapies that fundamentally reverse degenerative and chronic diseases. Therapies include gene and RNA vectors, biologics, compounds, stem cells, as well as diagnostics and technologies that support such therapies. Biohebe collaborates with a range of different entities including university laboratories, academic institutes, hospitals and early stage biotech companies.  All therapies show exceptional results at the rodent level and in diseased human cells.

Christina Galbraith established Biohebe in 2017 and has collaborated with hospitals, universities, academic and national institutes both in Europe and the United States to further the commercialization of  preclinical therapies treating a range of degenerative and congenital diseases including glaucoma, idiopathic pulmonary fibrosis and end stage liver disease from MASH/metAld. Prior to her focus and dedication to degenerative diseases, Christina collaborated with labs treating inherited diseases such as Usher Syndrome in children as well as furthering diagnostics in oncology including microfluidic filtration of circulating tumor cells. 

Christina is a published science journalist for Newsweek, Technomy and Futurism.

Biohebe is headquartered in New York City, NY.